Finally, since both RALA and RHEB have been involved in Ras-mediated oncogenic transformation, direct inhibition of these proteins could be an alternative therapy, single or in combination, to treat tumours with oncogenic RAS mutations. This evidence concerns the gene RALA and neoplasm.